Pradigastat (LCQ-908)
This product is for research use only, not for human use. We do not sell to patients.
For small sizes, please check our retail website as below: www.invivochem.com
| Size | Price | Stock |
|---|---|---|
| 100mg | $1450 | To Be Confirmed |
| 200mg | $2175 | To Be Confirmed |
| 500mg | $3670 | To Be Confirmed |
: Cat #: V4537 CAS #: 956136-95-1 Purity ≥ 98%
Description: Pradigastat (formerly also known as LCQ-908; LCQ908) is a novel, potent and orally bioavailable diacylglycerol acyltransferase 1 (DGAT1) inhibitor being developed for the treatment of familial chylomicronemia syndrome.
Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 455.47 |
|---|---|
| Molecular Formula | C25H24F3N3O2 |
| CAS No. | 956136-95-1 |
| Storage | -20℃ for 3 years in powder formr |
| -80℃ for 2 years in solvent | |
| SMILES Code | FC(F)(C1=NC=C(NC2=CN=C(C3=CC=C([C@H](CC4)CC[C@H]4CC(O)=O)C=C3)C=C2)C=C1)F |
| Synonyms | LCQ-908; LCQ908; LCQ 908; Pradigastat |
| Protocol | In Vitro | Pradigastat inhibits breast cancer resistance protein (BCRP)-mediated efflux activity in a dose-dependent fashion in a BCRP over-expressing human ovarian cancer cell line with an IC50 value of 5 μM. Pradigastat inhibits OATP1B1, OATP1B3, and OAT3 activity in a concentration-dependent manner with estimated IC50 values of 1.66 μM, 3.34 μM, and 0.973 μM, respectively. |
|---|---|---|
| In Vivo | Pradigastat (LCQ-908) inhibits the postprandial triglyceride levels in rats, dogs and monkeys. In rats whose lipoprotein lipase (LPL) activity has been abolished, Pradigastat reduces the postprandial accumulation of plasma triglyceride. Pradigastat decreases the postprandial rate of chylomicron triglyceride (CM-TG) secretion into the lymphatic duct and reduces the size of chylomicrons. |
These protocols are for reference only. InvivoChem does not
independently validate these methods.
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 2.1955 mL | 10.9777 mL | 21.9553 mL | 43.9107 mL |
| 5mM | 0.4391 mL | 2.1955 mL | 4.3911 mL | 8.7821 mL |
| 10mM | 0.2196 mL | 1.0978 mL | 2.1955 mL | 4.3911 mL |
| 20mM | 0.1098 mL | 0.5489 mL | 1.0978 mL | 2.1955 mL |
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start)
×
Volume(start)
=
Concentration(final)
×
Volume(final)
This equation is commonly abbreviated as: C1 V1 = C2 V2
Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg
Average weight of animals g
Dosing volume per animal µL
Number of animals
Step Two: Enter the in vivo formulation
%DMSO
+
%
+
%Tween 80
+
%ddH2O
Calculation Results:
Working concentration:
mg/ml;
Method for preparing DMSO master liquid:
mg
drug pre-dissolved in
µL
DMSO(Master liquid concentration
mg/mL)
,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:
Take
µL
DMSO master liquid, next add
µL
PEG300, mix and clarify, next add
µL
Tween 80,mix and clarify, next add
µL
ddH2O,mix and clarify.
Note:
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.